Urothelial Cancer Clinical Trials

Find Urothelial Cancer Clinical Trials Near You

Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma. An Investigator-Initiated, Prospective, Multicenter, Non-Interventional Trial.

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

P-EVOLVE is a prospective, multicenter, non-interventional observational study in adults with muscle-invasive urothelial carcinoma who receive perioperative treatment with enfortumab vedotin and pembrolizumab as part of routine clinical care. The study is designed to describe how peripheral neuropathy develops and changes during treatment and whether symptoms persist at the end of treatment. Peripheral neuropathy will be assessed using patient-reported questionnaires, standardized neurological examinations, and nerve conduction studies. The study will also assess neuropathic pain, neurotoxicity-related quality of life, depressive symptoms, and changes in taste and smell. Objective gustatory function will be evaluated using standardized Taste Strip testing. Study assessments will be performed before treatment, during the neoadjuvant and adjuvant treatment phases, around radical cystectomy, and at the end of treatment. Participation in the study does not determine whether treatment is started or how treatment is given. All anticancer treatment decisions remain part of routine clinical care. The study aims to improve understanding of the onset, severity, longitudinal course, and persistence of peripheral neuropathy associated with perioperative enfortumab vedotin and pembrolizumab and to compare patient-reported symptoms with objective neurological and neurophysiological findings.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients ≥18 years of age at the time of signing the informed consent form (ICF)

• Patients with histologically confirmed muscle-invasive urothelial carcinoma

• Patients who have not received any prior systemic treatment for muscle-invasive bladder cancer

• Patients who are eligible to receive enfortumab ve-dotin and pembrolizumab according to the respec-tive medicinal product information

Locations
Other Locations
Germany
Department of Urology, Klinikum rechts der Isar, Technical University Munich
RECRUITING
Munich
Department of Urology, Krankenhaus Barmherzige Brüder
RECRUITING
Munich
Department of Urology, LMU University Hospital, Ludwig-Maximilians-University Munich
RECRUITING
Munich
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2028-12
Participants
Target number of participants: 79
Sponsors
Collaborators: Department of Urology, TUM Klinikum rechts der Isar, Munich, Germany, Department of Urology, Krankenhaus Barmherzige Brüder, Munich, Germany, Department of Urology, LMU University Hospital, Munich, Germany
Leads: Comprehensive Cancer Center Munich (CCCM)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials